Orthocell Ltd (ASX: OCC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Orthocell Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $145.86 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 209.58 million
Earnings per share -0.036
Dividend per share N/A
Year To Date Return 7.32%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Orthocell Ltd (ASX: OCC)
    Latest News

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Orthocell (ASX:OCC) share price surges 13% on study success

    Shares in the medical company are surging today.

    Read more »

    ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
    Healthcare Shares

    Why the Orthocell (ASX:OCC) share price is flying higher today

    Orthocell reports promising results on nerve repair for patients following serious injury.

    Read more »

    medical doctor performing surgery using surgical instruments
    Healthcare Shares

    Here's why the Orthocell (ASX:OCC) share price is on the move today

    The company has taken another step in getting one of its star products internationally patented.

    Read more »

    Five stacked building blocks with green arrows, indicating rising inflation or share prices
    Healthcare Shares

    The Orthocell (ASX:OCC) share price is on the rise today. Here's why

    The Orthocell Limited (ASX: OCC) share price is up with news the company's hoping to fast-track its US approval after…

    Read more »

    Tooth and dentist tool on blue background
    Share Market News

    Why the Orthocell (ASX:OCC) share price is edging higher today

    The Orthocell Ltd (ASX: OCC) share price is edging higher today following a positive update in regards to CelGro. Here's…

    Read more »

    A male ASX investor wearing glasses and a beanie and denim shirt puts his hand to his chin wondering whether to buy ASX shares
    Share Market News

    Why is the Orthocell (ASX:OCC) share price falling today?

    The Orthocell Ltd (ASX: OCC) share price is sinking this afternoon despite a positive update on its CelGro product.

    Read more »

    Surge in ASX share price represented by happy woman pointing to her big smile
    Share Market News

    Why the Orthocell (ASX:OCC) share price is on the rise

    The Orthocell Ltd (ASX: OCC) share price is rising after the company announced an earlier than expected positive update. Here's…

    Read more »

    ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
    Share Market News

    Why the Orthocell (ASX:OCC) share price is rocketing 23% higher

    The Orthocell Ltd (ASX: OCC) share price is one of the best performers on the market today. This comes after…

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why the Orthocell (ASX:OCC) share price has popped 6% today

    The Orthocell Ltd (ASX: OCC) share price is surging higher today. This comes after the company received Australian market approval…

    Read more »

    asx medical share price represented by x-ray or people shaking hands
    Share Market News

    Why the Orthocell (ASX:OCC) share price is edging higher today

    The Orthocell (ASX: OCC) share price is edging higher as the company said it has completed an important step in…

    Read more »

    Share Market News

    Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials

    The Orthocell Ltd (ASX: OCC) share price has rocketed more than 17% after positive results for the company's nerve repair…

    Read more »

    a woman
    Share Market News

    The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough

    Orthocell Ltd (ASX: OCC) is reporting a blockbuster medical breakthrough.

    Read more »

    OCC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Orthocell Ltd

    Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.

    OCC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Nov 2024 $0.61 $-0.01 -1.61% 1,913,148 $0.63 $0.63 $0.61
    31 Oct 2024 $0.62 $0.00 0.00% 1,108,360 $0.62 $0.64 $0.62
    30 Oct 2024 $0.62 $-0.03 -4.65% 830,467 $0.65 $0.65 $0.62
    29 Oct 2024 $0.65 $0.00 0.00% 381,124 $0.65 $0.65 $0.63
    28 Oct 2024 $0.65 $-0.04 -5.84% 935,689 $0.69 $0.69 $0.64
    25 Oct 2024 $0.69 $0.00 0.00% 1,324,139 $0.64 $0.69 $0.62
    23 Oct 2024 $0.69 $-0.04 -5.52% 731,108 $0.71 $0.72 $0.67
    22 Oct 2024 $0.73 $0.05 7.41% 1,122,822 $0.69 $0.75 $0.68
    21 Oct 2024 $0.68 $0.02 3.03% 529,952 $0.66 $0.71 $0.66
    18 Oct 2024 $0.66 $0.00 0.00% 421,910 $0.67 $0.67 $0.65
    17 Oct 2024 $0.66 $-0.05 -7.04% 1,006,377 $0.69 $0.69 $0.65
    16 Oct 2024 $0.71 $-0.02 -2.74% 1,249,455 $0.72 $0.74 $0.68
    15 Oct 2024 $0.73 $0.10 15.75% 1,510,085 $0.64 $0.73 $0.63
    14 Oct 2024 $0.64 $-0.03 -4.55% 1,734,322 $0.68 $0.70 $0.61
    11 Oct 2024 $0.66 $-0.01 -1.50% 3,773,497 $0.68 $0.77 $0.65
    10 Oct 2024 $0.67 $0.12 21.82% 3,169,316 $0.57 $0.68 $0.57
    09 Oct 2024 $0.55 $0.04 7.77% 1,568,541 $0.53 $0.55 $0.53
    08 Oct 2024 $0.52 $0.04 8.33% 2,593,557 $0.51 $0.53 $0.50
    07 Oct 2024 $0.48 $0.02 4.35% 688,340 $0.47 $0.49 $0.47
    04 Oct 2024 $0.46 $0.01 2.20% 189,527 $0.46 $0.47 $0.46
    03 Oct 2024 $0.46 $0.05 12.20% 653,009 $0.42 $0.46 $0.41

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Oct 2024 Paul Anderson Buy 80,426 $58,710
    Exercise of options.
    15 Oct 2024 Paul Anderson Exercise 5,200,000 $3,796,000
    Exercise of options. Cashless exercise of Unlisted Options.
    15 Oct 2024 Paul Anderson Buy 268,089 $195,704
    Exercise of options. Cashless exercise of Unlisted Options.
    24 Apr 2024 John Wielen Buy 20,000 $7,622
    On-market trade.
    15 Apr 2024 John Wielen Buy 35,000 $13,646
    On-market trade.
    17 Jan 2024 Kim Beazley AC Issued 2,000,000 $820,000
    Issue of options.
    20 Nov 2023 Fiona Wood Issued 2,000,000 $820,000
    Issue of options.
    15 Nov 2023 John Wielen Issued 250,000 $91,250
    Issue of securities.
    07 Nov 2023 Paul Anderson Issued 500,000 $192,500
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Fiona Melanie Wood Non-Executive Director Nov 2023
    Professor Wood has over 30 years of experience as a plastic and reconstructive surgeon. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children's Hospital, and the Winthrop Professor of Surgery at the University of Western Australia.
    Mr Paul Frederick Anderson Managing Director Mar 2006
    Mr Anderson has over 20 years of experience in the medical device and regenerative medicine fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has expertise in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings.
    Dr Ravi Thadhani Non-Executive Director Mar 2023
    Dr Thadhani is an Independent Non-Executive director of Orthocell who has co-authored more than 300 scientific publications, including articles in medical journals. Dr Thadhani has more than 30 years as a general and specialised physician, researcher, medical administrator and commercialisation adviser and has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. Dr Thadhani has served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors and has acted as expert advisor to multiple global pharmaceutical companies including Sandoz, Shore, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring.
    Mr John Van Der Wielen Non-Executive ChairmanNon-Executive Director Jun 2023
    Mr Wielen has over 30 years in wealth management, private banking, investments, and insurance, which includes executive positions in global financial services groups. These positions allowed Wielen to work in London, Luxemburg, Malaysia, Sydney and Perth, for brands such as Crown Resorts, Blackstone, HBF Health Ltd, Lloyds Banking Group, Lombard Assurance and ANZ Bank. Wielen currently holds the role of Chair, Crown Perth and is a Non-Executive Director on the Blackstone owned Crown Resorts Australia Ltd.
    Hon Kim Beazley AC Non-Executive Director Jan 2024
    Mr Beazley is an Independent Non-Executive director of Orthocell. Prior to this, Mr Beazley dedicated almost three decades to a career in Federal Parliament, representing the WA seats of Brand and Swan. Beazley held ministerial roles including Defence and Finance and served as Deputy Prime Minister and Leader of the Opposition. His parliamentary experience included committees on Intelligence, Foreign Affairs, Defence, and Trade.
    Mr Peter Webse Company Secretary Mar 2023
    -
    Peter Webse Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Ming Hao Zheng & Fan Ying 6,805,886 3.25%
    Mr Paul Frederick Anderson & Ms Nicole Jane Telford 6,233,335 2.97%
    Mr Qixiao Zhou 5,996,241 2.86%
    Mr Jia Xun Xu 5,014,107 2.39%
    HSBC Custody Nominees (Australia) Limited 4,420,632 2.11%
    Mr Patrick John McHale 4,300,000 2.05%
    Wenola Pty Ltd 3,609,058 1.72%
    Sankofa Strategic Equity Fund Limited 2,462,000 1.17%
    Citicorp Nominees Pty Ltd 2,448,297 1.17%
    The University of Western Australia 2,360,973 1.13%
    Dr John Clifford Philpott & Mrs Rebecca Anne Philpott 2,048,677 0.98%
    Sandini Pty Ltd 1,784,911 0.85%
    Miss Kate Imogen Leaver 1,698,762 0.81%
    Dr John Clifford Philpott 1,560,216 0.74%
    Mr Tony Athas & Mrs Angela Athas 1,430,000 0.68%
    Mr Vance Clark Moore 1,360,000 0.65%
    Carjay Investments Pty Ltd 1,351,352 0.64%
    Mr Bryan F Short 1,300,000 0.64%
    Dr Russell Kay Hancock 1,200,000 0.57%
    Aris Nominees Pty Ltd 1,042,816 0.50%

    Profile

    since

    Note